All In MedTech

FDA Clearance Tracker · P890027-S062

Nucleus Cochlear Implant Systems

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 31, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 31, 2022

Approved

Time to decision

188 days

Received Apr 26, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P890027-S062
Device name
Nucleus Cochlear Implant Systems
Applicant location
Lone Tree, CO
Received
Apr 26, 2022
Decided
Oct 31, 2022
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P890027

Device type

Device class
Class III

Every decision under product code MCM

FDA's approval statement

As written in FDA's record.

for a new sound processor (Nucleus 8 Sound Processor) and two supporting software devices (Custom Sound Pro and Nucleus Smart App)

Source documents

Other decisions for Cochlear Americas

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.